|Public on Feb 04, 2019
|LNCaP_DHT ENZ rep2
|cell line: LNCaP-FGC prostate adenocarcinoma cancer cell line
|Cells were pretreated with indicated inhibitors for 45 minutes followed by 24 hr stimulation with 5 nM DHT or EtOH.
|LNCaP-FGC cells were grown for 72 hrs in charcoal stripped (steroid free) serum,
|RNA was prepared by Qiazol extraction followed by RNeasy mini column (QIAGEN)
10 ug of total RNA was submitted to poly-A selection to remove ribosomal RNA and reverse transcribed to double-stranded cDNA. The cDNA was eblunt ended, adenylated, and ligated with Illumina indexes.
|Illumina HiSeq 3000
|Illumina Casava1.8 software used for basecalling
Reads were aligned using the OmicSoft aligner and gene expression quantified based on UCSC gene model.
Differentially expressed genes between treatment conditions detected by DESeq2 with a statistical cut-off (FC>2, p<0.01)
|Aug 06, 2018
|Last update date
|Feb 04, 2019
|1 North Waukegan Rd
|Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability (LNCaP RNA-seq)
|Selective Inhibition of the Second Bromodomain of BET Family Maintains Anti-Tumor Efficacy and Improves Tolerability